ArticleNeuropsychiatric disease and treatment2026
Real-World Assessment of Transcranial Direct Current Stimulation (tDCS) Combined with Sertraline in the Treatment of Depression in Vietnam.
Article in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Major depressive disorder (MDD) is a leading cause of disability worldwide. While selective serotonin reuptake inhibitors (SSRIs) such as Sertraline are widely used, a substantial proportion of patients achieve only partial remission. Transcranial direct current stimulation (tDCS), a non - invasive neuromodulation technique, has been approved and implemented as a clinical procedure in Vietnam. This study aimed to assess the real - world effectiveness of combining tDCS with Sertraline in patients with MDD. Methods: This open-label, randomized real-world study was conducted at 103 Military Hospital. A total of 140 inpatients with MDD were allocated to receive either Sertraline alone (n = 70) or Sertraline plus tDCS (n = 70) as part of routine care. Depression severity was evaluated using the Beck Depression Inventory (BDI) and Hamilton Depression Rating Scale (HAMD), and serum serotonin levels were measured at baseline and after a three - week treatment period. Statistical analyses included repeated - measures ANOVA and ordinal logistic regression. Results: Both groups demonstrated significant reductions in BDI and HAMD scores over time (p < 0.001). However, the Sertraline + tDCS group exhibited a significantly greater increase in serum serotonin (+ 30.3 vs + 20.0 ng/mL, p < 0.0001) and greater symptom improvement. Logistic regression indicated a higher likelihood of clinical response in the tDCS group (BDI: OR ≈ 4.3, p = 0.032; HAMD: OR ≈ 6.5, p = 0.018). Conclusion: In a real - world clinical setting in Vietnam, adjunctive tDCS combined with Sertraline was associated with enhanced biological and clinical outcomes in MDD patients. These findings provide supportive evidence for the integration of tDCS into standard psychiatric care, although further controlled studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.